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Complete heart block occurs in 4% to 15% of cases offetal arrhythmia. Although it is usually well toleratedin the absence of complicating cardiac anomalies, asmany as 25% of these fetuses have hydrops and die in
utero.1 The pathophysiologic arguments for fetal ventricular pac-
ing are compelling. We describe the case of a fetus presenting with
complete heart block, hydrops, and associated structural heart
defects, the mother of whom consented to attempts at in utero
pacing. The purpose of this article is to describe a new lead for
percutaneous implantation that minimizes surgical trauma to both
the fetus and the mother.
Clinical Summary A 36-year-old woman was referred to the
Institute of Cardiology Porto Alegre at 18 weeks’ gestation with a
fetus presenting with complete heart block (heart rate, 47 beats/
min), marked hydrops, left atrial isomerism, and an atrioventricu-
lar septal defect. Maternal therapy with positive chronotropic
drugs and steroids did not reverse the low output failure and low
fetal heart rate. A follow-up maternal ultrasound examination at 24
weeks’ gestation suggested decreased right ventricular contractil-
ity in the fetus and abdominal and pleural effusions.
With the risk of fetal demise approaching 100%, fetal pacing
was considered. After extensive discussions with the physicians
involved with the Fetal Cardiology Research Program of the Heart
Institute University of Sa˜o Paulo and the Institute of Cardiology
Porto Alegre, including explanation of the procedure’s benefits and
risks, the patient consented to attempts at in utero transthoracic
fetal ventricular pacing. The procedure was performed at 25
weeks’ gestation according to a protocol approved by our institu-
tional ethics committee on human research.
Anesthesia. The mother was sedated with intravenous
midazolam and fentanyl citrate. Xylocaine 1% was infiltrated
subcutaneously in
her abdomen in
preparation for chor-
docentesis. The pla-
cental cord was then
punctured transpla-
centally, under ul-
trasonographic
guidance, with an
18-gauge needle.
Pancuronium and
ketamine were administered to the fetus.
The new lead. We recently designed a prototype T-shaped
lead that can be introduced through an 18-gauge needle to fix
securely to the fetal myocardium, with no need for open surgical
procedures. The lead represents a modification of the temporary
epicardial pacing lead commonly used after heart surgery. The
main difference is that at the cardiac end, the pacing lead is cut
close to the polypropylene coating, and a stainless-steel bar (5 mm
 0.5 mm) is connected to the wire, producing a T-bar. The
purpose of this shape is to keep the new lead securely anchored to
the myocardium, thus preventing lead dislodgment. The other end
of the lead remains intact, consisting of a long straight needle. The
lead length remained the original 60 cm.
In the present case the new pacing lead was driven to the heart
of the fetus through the tip of a specially designed, 15-cm, 18-
gauge introducer needle with a 25° beveled tip. This tip contained
a 7-mm longitudinal side slot cut from the heel of the bevel that
housed the T-bar. The T-bar was positioned within the lumen at the
tip of the needle, and the pacing wire protruded from the slot and
trailed alongside the needle (Figure 1). Use of a needle stylet was
planned to eject the T-bar from the slot.
Fetal pacing procedure. The site for lead introduction was
marked on the mother’s abdomen, and local anesthesia was ap-
plied. Under continuous scanning, the new lead was inserted into
the uterine cavity and advanced into the fetal thorax and then the
ventricle. The fetus was in the dorsal presentation, making it
difficult to reach the ventricles. After 4 attempts, the needle tip hit
the myocardium. The needle stylet was gently advanced into the
needle lumen, and the T-bar lead was ejected from the introducer
needle slot into the myocardium by pressing the needle stylet
forward. The introducer needle was then withdrawn. A second
lead was placed in the thoracic wall for bipolar stimulation. The
leads were then connected to the pacing system analyzer
(Biotronik ERA 300; Berlin, Germany) to measure the sensi-
tivity and stimulation thresholds. Ventricular pacing was begun
at 140 beats/min. Stimulation resistance was measured during
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constant-voltage pacing (5 V) at a pulse duration of 0.5 ms. We
measured a stimulation resistance of 357 and a sensed fetal R
wave of 6.4 mV. During the procedure, cardiac tamponade
developed, which was managed with pericardiocentesis.
Fetal myocardial stimulation threshold. Measurements were
made at constant pulse width pacing until the lowest output
provided 100% ventricular capture. Stimulation thresholds were
obtained at pulse widths ranging from 0.1 to 2.0 ms by gradu-
ally decreasing the voltage output of the pulse analyzer to the
point at which ventricular noncapture was apparent with bra-
dycardia. The acute fetal myocardial stimulation thresholds
were consistently low, with no stimulation failure seen with the
new electrode. The curve remained relatively constant at pulse
widths of greater than 0.6 ms, turning sharply upward with
shorter pulse widths of less than 0.6 ms. After all measurements
were completed, the leads were connected to a Biotronik Actros
SR single-chamber pulse generator, which was implanted sub-
cutaneously in the maternal abdominal wall. The pacemaker
was set to the following parameters: VVI mode; pacing rate,
140 pulses/min; cardiac sensitivity, 1.25 mV; cardiac pulse
amplitude, 5.0 V; and refractory period, 400 ms. During the first
postoperative day, an echocardiogram revealed recovery of
ventricular function, a stable fetal heart rate of 140 beats/min,
and a mild pericardial effusion. No uterine contractions were
observed during the postoperative period. Again, low stimula-
tion thresholds and no stimulation failures were seen. Figure 2
shows the voltage strength-duration curves obtained during the
procedure (ie, implantation) and on the first postoperative day.
After 36 hours of ventricular pacing, asystole was noticed on
ultrasonography, and the pericardial effusion appeared signifi-
cant. The pregnancy was subsequently terminated through a
cesarean section, resulting in the delivery of an 800-g hydropic
infant.
Fetal Autopsy. Postmortem examination confirmed massive
hydrops and cardiac anatomic defects. A moderate bloody effusion
in the pericardial sac was considered the probable cause of fetal
death. One pacing lead was firmly placed in the left ventricle’s
muscle, and the other lead was also placed in the thoracic wall. No
hematoma was observed in the ventricular wall, nor were thrombi
seen within the ventricles.
Discussion
The T-bar lead proposed here for use in percutaneous fetal
pacing might offer important technical advantages over leads
used in conventional open surgical procedures. During the
observed period of fetal pacing, our lead provided stable fixa-
tion with acceptable performance, as demonstrated by the low
acute thresholds. Indeed, we believe that this is the first docu-
mentation of voltage strength-duration curves for the acute
myocardial stimulation threshold of a human fetus that survived
36 hours after intrauterine pacemaker implantation. Moreover,
this technique has the potential to minimize surgical trauma to
both the fetus and the mother.
The cardiac tamponade observed in this case could have
resulted from the 3 failed attempts at lead placement. We
believe that use of fetoscopy in conjunction with ultrasono-
graphic guidance would allow for a more controlled procedure
in which the new lead could be more easily placed.2 In addition,
the development of improved materials, such as a thinner needle
(20 gauge) and a bipolar pacing wire, could facilitate puncture
of the fetal myocardium, thus decreasing the chances of such a
complication.
In the present case the fetal heart rate abruptly increased from 47
to 140 beats/min with pacing. Nevertheless, bradyarrhythmia, with a
heart rate 50% of the normal fetal rate, is well tolerated in the absence
of complicating systemic abnormalities or placental insufficiency.
Therefore, it seems to us that a gradual increase in the fetal heart rate
would be more adaptive and could adequately augment the cardiac
output as well. It also is unclear whether such a jump in the fetal heart
rate could result in any acid-base imbalances caused by increasing
myocardial oxygen consumption and cardiac output.
Previous attempts at in utero percutaneous pacing, either through
a transthoracic approach1 or through the inferior vena cava,3 have
resulted in fetal demise a few hours after the procedure. A lack of
myocardial fixation and consequent dislodgment of the percutaneous
lead represents a major technical limitation of the percutaneous ap-
proach. Although the authors have demonstrated that the pacing wires
can be satisfactorily positioned within the heart, they could not pre-
vent dislodgement with resumption of fetal activity. Our new proto-
type lead has the length increased from 60 to 150 cm to avoid this
problem. Attempts at direct pacemaker implantation through a cesar-
ean section were undertaken at the University of California, San
Figure 1. The introducer needle with the new T-bar lead: A,
stainless steel bar; B, pacing wire with polypropylene coating; C,
straight needle; D, 18-gauge introducer needle with a 25° beveled
tip fashioned with a 7-mm longitudinal side slot cut from the heel
of the bevel (E); F, needle stylet.
Figure 2. Voltage strength-duration curves for acute myocardial
stimulation threshold of a human fetus during lead implantation
(implant) and on the first postoperative day (1st POD).
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Francisco,4 and at the Institute of Cardiology Porto Alegre, both of
which were unsuccessful.
In our previous experimental study,5 we described the use of an
epicardial modified screw-in lead to pace fetuses with complete
heart block through a cesarean section as a safer and more reliable
procedure. However, the possibility of premature labor still repre-
sents a challenge for fetal surgery.6 The percutaneous approach
associated with this new lead for fetal ventricular pacing seems to
be more compelling and less invasive. Moreover, it should be a
relatively inexpensive, simple, and quick alternative to classic
surgical placement of an epicardial lead.
We thank Dr Jose Antonio Franchini Ramirez, Director of the
Heart Institute (InCor), University of Sa˜o Paulo Medical School,
and Dr Ivo Nesralla, Director of the Institute of Cardiology Porto
Alegre, for facilitating the agreement between the 2 involved
institutions. This agreement permitted this successful collaborative
effort at fetal pacing to occur.
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